Coley's toxin revisited: immunotherapy or plasminogen activator therapy of cancer?

Zacharski, Leo R.; Sukhatme, Vikas P.

doi:10.1111/j.1538-7836.2005.01110.x

Cited by 53 publications

(38 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The enhancement in CTLs is associated with a rise in the ratio of CD8 + to FoxP3 + cells, indicating the enhancement of protective immunity and a reduction in immunosuppressive mechanisms. The rise in effector T cells coincides with durable protection in both prophylactic and therapeutic models of B16-F10 melanomas building upon prior GVAX studies and biomaterial vaccination approaches 2,3,53 . Although, the response of cytotoxic and helper T cells was explored, the role of melanoma-specific CD8 + T cells was not investigated.…”

Section: Discussionmentioning

confidence: 90%

Injectable cryogel-based whole-cell cancer vaccines

et al. 2015

View full text Add to dashboard Cite

A biomaterial-based vaccination system that uses minimal extracorporeal manipulation could provide in situ enhancement of dendritic cell (DC) numbers, a physical space where DCs interface with transplanted tumor cells, and an immunogenic context. Here we encapsulate GM-CSF, serving as a DC enhancement factor, and CpG ODN, serving as a DC activating factor, into sponge-like macroporous cryogels. These cryogels are injected subcutaneously into mice to localize transplanted tumor cells and deliver immunomodulatory factors in a controlled spatio-temporal manner. These vaccines elicit local infiltrates composed of conventional and plasmacytoid DCs, with the subsequent induction of potent, durable, and specific anti-tumor T cell responses in a melanoma model. These cryogels can be delivered in a minimally invasive manner, bypass the need for genetic modification of transplanted cancer cells, and provide sustained release of immunomodulators. Altogether, these findings indicate the potential for cryogels to serve as a platform for cancer cell vaccinations.

show abstract

Section: Discussionmentioning

confidence: 90%

Injectable cryogel-based whole-cell cancer vaccines

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The idea of using bacteria as anticancer ("immunotherapy") agents dates back to ca. 1890 when William B. Coley, a surgeon, observed that a patient with neck cancer showed recovery after developing an erysipelas infection (20).…”

Section: Microbiology and Cancermentioning

confidence: 99%

Cancer in North Cyprus: 2. Biomedical Research Activities

Djamgoz¹,

Akün²,

Arslan³

et al. 2017

Cyprus J Med Sci

View full text Add to dashboard Cite

This is the second part of a two-part review on the cancer status of North Cyprus. Here, we give an overview of the various areas of research on cancer. There are four main areas of ongoing biomedical investigation. First, monitoring of possible carcinogenic chemical factors in the environment (soil and water) is focused on arsenic. Arsenic has been found to exist broadly over the island at levels above the minimum level advised by the Environmental Protection Agency. At present, the source(s) of environmental arsenic is unclear. Second, pathophysiological mechanisms of breast and prostate cancer are being investigated with a focus on ion channels (particularly, the voltage-gated sodium channel) driving the metastatic process. In particular, the triangular relationship involving the channel, its persistent current component, and tumor hypoxia is being elucidated. Third, a further emerging theme is the association of microbiota with cancer. The possible roles of bacterial infections or microbiota in preventing, treating, or causing several types of cancers are among these projects. Fourth, a range of developments in nanotechnology is being considered. It is concluded that the island offers significant opportunities for internationally competitive, multi-faceted research on cancer.

show abstract

“…In the early 1890s, Dr. William Coley noticed a reduction in tumor size of patients with bacterial infections. He began injecting live bacteria into the tumors, and later developed a safer concoction, termed "Coley's toxins", with mixed results [51]. Over time, the field shifted away from cancer immunology research, as cytokines and immune cell types became well defined, yet cancer treatment with interleukins and other cytokines yielded variable results.…”

Section: The Re-emergence Of Cancer Immunotherapymentioning

confidence: 99%

A Quantitative Systems Pharmacology Perspective on Cancer Immunology

Byrne-Hoffman

Klinke

2015

Processes

View full text Add to dashboard Cite

Abstract:The return on investment within the pharmaceutical industry has exhibited an exponential decline over the last several decades. Contemporary analysis suggests that the rate-limiting step associated with the drug discovery and development process is our limited understanding of the disease pathophysiology in humans that is targeted by a drug. Similar to other industries, mechanistic modeling and simulation has been proposed as an enabling quantitative tool to help address this problem. Moreover, immunotherapies are transforming the clinical treatment of cure cancer and are becoming a major segment of the pharmaceutical research and development pipeline. As the clinical benefit of these immunotherapies seems to be limited to subset of the patient population, identifying the specific defect in the complex network of interactions associated with host immunity to a malignancy is a major challenge for expanding the clinical benefit. Understanding the interaction between malignant and immune cells is inherently a systems problem, where an engineering perspective may be helpful. The objective of this manuscript is to summarize this quantitative systems perspective, particularly with respect to developing immunotherapies for the treatment of cancer. OPEN ACCESSProcesses 2015, 3 236

show abstract

Coley's toxin revisited: immunotherapy or plasminogen activator therapy of cancer?

Cited by 53 publications

References 45 publications

Injectable cryogel-based whole-cell cancer vaccines

Injectable cryogel-based whole-cell cancer vaccines

Cancer in North Cyprus: 2. Biomedical Research Activities

A Quantitative Systems Pharmacology Perspective on Cancer Immunology

Contact Info

Product

Resources

About